Traxlink PB 650 Tablet contains Tranexamic Acid 500 mg (Sustained Release) and Pine Bark Extract 150 mg, a specialized combination formulated to help manage excessive bleeding while providing enhanced antioxidant and vascular support. The sustained-release formulation of Tranexamic Acid helps maintain effective therapeutic levels over an extended duration, while the higher concentration of Pine Bark Extract offers additional support for blood vessel integrity and healthy microcirculation. The medicine is prescribed under medical supervision for conditions associated with abnormal or excessive bleeding.
Tranexamic Acid works by inhibiting the conversion of plasminogen to plasmin, thereby reducing fibrinolysis and helping stabilize blood clots to control bleeding effectively. The sustained-release technology provides prolonged antifibrinolytic activity for consistent therapeutic benefit. Pine Bark Extract is rich in procyanidins and natural antioxidants that help support vascular health, improve circulation, and protect tissues from oxidative stress. Together, these ingredients provide a comprehensive approach to bleeding management and vascular support.
The tablet is commonly prescribed for heavy menstrual bleeding (menorrhagia), gynecological bleeding disorders, postoperative bleeding, and other conditions requiring antifibrinolytic therapy as advised by a healthcare professional. Appropriate use may help reduce blood loss, improve patient comfort, and support overall treatment outcomes. The dosage and duration of therapy should always be individualized according to the patient's clinical condition and the physician's recommendations.
With the increasing prevalence of gynecological disorders and the growing demand for advanced hemostatic therapies, Traxlink PB 650 Tablet maintains strong relevance in the gynecology and hematology segments. Its sustained-release formulation, higher antioxidant support, physician confidence, and broad clinical utility contribute to sustained market demand. The product offers valuable business opportunities and long-term growth prospects for retailers and distributors operating within the pharmaceutical hemostatic sector.